- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Toshiba extends ultrasound reach in breast imaging
Toshiba America Medical Systems has positioned its MicroPure ultrasound technology as a way to better characterize microcalcifications. The new technology, showcased at RSNA 2008 on Toshiba’s Aplio XG ultrasound scanner, improves the detection of small calcifications that otherwise may evade detection with ultrasound.
Toshiba America Medical Systems has positioned its MicroPure ultrasound technology as a way to better characterize microcalcifications. The new technology, showcased at RSNA 2008 on Toshiba's Aplio XG ultrasound scanner, improves the detection of small calcifications that otherwise may evade detection with ultrasound.
The company also presented its work-in-progress ElastoQ, which displays differences in the relative elasticity of tumor and surrounding tissue by assigning colors to a tomographic image or, alternatively, as a graph. When using ElastoQ, tissue is examined while it is slightly compressed and then when it is decompressed. Cancerous tissue tends to have a significantly lower elasticity than healthy tissue. Like MicroPure, ElastoQ runs on the Toshiba Aplio XG.
Accompanying these advances is the company's new 18-MHz high-resolution Dynamic Micro Slice transducer for breast imaging.
The company is positioning its proprietary version of elastography as a possible future means to assess tumors, while framing MicroPure as a complementary way to detect small calcifications. Although ElastoQ is not yet cleared by the FDA, MicroPure has passed FDA review.
MicroPure has not yet been clinically validated, however, which is why the company is showing only early results from its clinical collaborators, leaving claims to a later date.
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
FDA Clears Controlled Contrast Delivery Method for Ultrasound Imaging of Fallopian Tubes
September 9th 2024Facilitating natural contrast delivery through an intrauterine catheter, FemChec can be utilized for ultrasound assessment of fallopian tubes and may provide diagnostic confirmation for an emerging non-surgical option for permanent birth control.
Mammography Study: Can Stand-Alone AI Enhance Detection of Interval Breast Cancer?
August 28th 2024Identifying over 23 percent of interval breast cancers with a 96 percent sensitivity in mammography interpretation, an emerging AI software also facilitated correct localization in over 75 percent of cases involving interval breast cancer, according to new research.
FDA Clears Emerging Cardiovascular Point-of-Care Ultrasound Platform
August 22nd 2024Combining four CAD modules for valvular pathologies with a variety of automated measurements, the AI-enabled AISAP Cardio ultrasound system reportedly facilitates up to a 90 percent accuracy rate in detecting common cardiac conditions.
